



*structure search  
for claim 15*



chain nodes :

7 8 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

2-7 5-8 7-9 9-10 9-11

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-7 7-9

exact bonds :

5-8 9-10 9-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS  
11:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE  
NEWS 5 Jul 21 Identification of STN records implemented  
NEWS 6 Jul 21 Polymer class term count added to REGISTRY  
NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and  
Right Truncation available  
NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in  
September 2003  
NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in  
September 2003  
NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in  
September 2003  
NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in  
September 2003  
NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:09:20 ON 19 SEP 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:09:28 ON 19 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

DICTIONARY FILE UPDATES: 18 SEP 2003 HIGHEST RN 588668-76-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09788315.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:09:45 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS  
SEARCH TIME: 00.00.01


5 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 768 TO 1712  
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> d scan

L2 5 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN  
IN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI)  
MF C19 H25 Cl2 N3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>


Uploading 09788315.str

L3 STRUCTURE UPLOADED

=> d l3

L3 HAS NO ANSWERS

L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 14:10:55 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS  
SEARCH TIME: 00.00.01


10 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 768 TO 1712  
PROJECTED ANSWERS: 11 TO 389

L4 10 SEA SSS SAM L3

=> d scan

L4 10 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN  
IN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy-  
(9CI)  
MF C20 H29 N3 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 10 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN  
IN Pyrazinamine, 5-[2-chloro-4-(1-methylethoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI)

MF C21 H30 Cl N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=&gt; s l3 ful

FULL SEARCH INITIATED 14:11:11 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1323 TO ITERATE

100.0% PROCESSED 1323 ITERATIONS

198 ANSWERS

SEARCH TIME: 00.00.01

L5 198 SEA SSS FUL L3

=&gt; fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.95

149.16

FILE 'CAPLUS' ENTERED AT 14:11:26 ON 19 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2003 VOL 139 ISS 13

FILE LAST UPDATED: 18 Sep 2003 (20030918/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; s l5

L6

10 L5


=&gt; d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):1

YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

GI



AB The invention provides compds. useful as PGI<sub>2</sub> receptor agonist and pharmaceutical compns., particularly pharmaceutical compns. contg. as the active ingredient compds. represented by the general formula (I) or pharmaceutically acceptable salts thereof [wherein R<sub>1</sub> and R<sub>2</sub> are each independently optionally substituted aryl; Y is N, N(O), or optionally substituted CH; Z is N or optionally substituted CH; A is optionally substituted NH, O, S, SO, SO<sub>2</sub>, or ethylene; D is an optionally hydroxy-substituted alkylene or alkenylene; or A and D together represents a bivalent group Q<sub>1</sub> (wherein m is an integer of 0-2; q is 2 or 3; n is an integer of 0-4); E is phenylene or a single bond; G is O, S, or optionally substituted CH<sub>2</sub>; R<sub>3</sub> and R<sub>4</sub> are each independently hydrogen or alkyl; and Q is carboxyl, alkoxycarbonyl, tetrazolyl, carbamoyl, mono- or dialkylcarbamoyl, CONHSO<sub>2</sub>R<sub>10</sub> (wherein R<sub>10</sub> is optionally substituted alkyl, aryl, aryloxy, or heterocyclyl)]. These compds. are useful as platelet aggregation inhibitors or remedies for chronic artery obstruction, intermittent limping (claudication) (Charcot's syndrome), or peripheral artery embolism. Thus, a soln. of 763 mg 5,6-diphenyl-2-(methylamino)pyrazine in 4 mL DMF was added 140 mg 60% NaH, stirred at 80.degree. for 30 min, and cooled in an ice bath followed by adding slowly a soln. of 657 mg Me 2-(4-bromobutyloxy)acetate in 2 mL DMF, and the resulting mixt. was stirred at room temp. for 14 h to give 240 mg Me 2-[4-[N-(5,6-diphenylpyrazin-2-yl)-N-methylamino]butyloxy]acetate (II). II was sapond. with a mixt. of 1 N aq. NaOH and MeOH under reflux for 2 h, followed by removing the solvent under reduced pressure, adding water, extg. the aq. soln. with Et<sub>2</sub>O, neutralizing it with 1 N aq. HCl, and extg. it with EtOAc to give 2-[4-[N-(5,6-diphenylpyrazin-2-yl)-N-methylamino]butyloxy]acetic acid (III). III showed IC<sub>50</sub> of 0.2 .mu.M for inhibiting the ADP (ADT)-induced aggregation of human blood platelet and at 1 .mu.M inhibited the [3H]-Iloprost binding on human platelet membrane by 85%. Pharmaceutical formulations, e.g. tablet contg. tert-Bu 2-[4-(5,6-diphenylpyrazin-2-ylsulfonyl)butyloxy]acetate, were described.

ACCESSION NUMBER: 2002:849591 CAPLUS

DOCUMENT NUMBER: 137:370112

TITLE: Preparation of derivatives of heterocyclic compounds such as pyridine, pyrimidine, 1,2,4-triazine, and pyrazine as antagonists of prostaglandin I<sub>2</sub> receptor

INVENTOR(S): Asaki, Tetsuo; Hamamoto, Taisuke; Kuwano, Keiichi

PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088084	A1	20021107	WO 2002-JP4118	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2001-129765 A 20010426

OTHER SOURCE(S): MARPAT 137:370112

IT 475084-96-9P 475084-99-2P 475085-01-9P

475085-47-3P 475085-49-5P 475085-51-9P


475086-26-1P 475086-98-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of derivs. of heterocyclic compds. as antagonists of prostaglandin I<sub>2</sub> receptor platelet aggregation inhibitor, or remedy for chronic artery obstruction, intermittent limping, or peripheral artery embolism)

RN 475084-96-9 CAPLUS


CN Acetic acid, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 475084-99-2 CAPLUS


CN Acetic acid, [4-[[5,6-bis(4-methylphenyl)pyrazinyl](1-methylethyl)amino]butoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RN 475085-01-9 CAPLUS

CN Acetic acid, [4-[(3-chloro-5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 475085-47-3 CAPLUS


CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 475085-49-5 CAPLUS


CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)






RN 475085-51-9 CAPLUS

CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl) (1-methylethyl) amino] butyl] sulfon  
yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 475086-26-1 CAPLUS

CN Sulfamic acid, [[4-[(5,6-diphenylpyrazinyl) (1-  
methylethyl) amino] butoxy] acetyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 475086-98-7 CAPLUS

CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl) (1-methylethyl) amino] butyl] thio]-  
(9CI) (CA INDEX NAME)



IT 475085-57-5P 475085-60-0P 475085-62-2P

475085-93-9P 475085-94-0P 475085-95-1P

475086-01-2P 475086-02-3P 475086-03-4P

475086-05-6P 475086-07-8P 475086-10-3P


475086-12-5P 475086-14-7P 475086-16-9P  
 475086-18-1P 475086-20-5P 475086-22-7P  
 475086-23-8P 475086-24-9P 475086-28-3P  
 475086-29-4P 475086-31-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(prepn. of derivs. of heterocyclic compds. as antagonists of  
 prostaglandin I<sub>2</sub> receptor platelet aggregation inhibitor, or remedy for  
 chronic artery obstruction, intermittent limping, or peripheral artery  
 embolism)


RN 475085-57-5 CAPLUS

CN Acetic acid, [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-  
 (9CI) (CA INDEX NAME)




RN 475085-60-0 CAPLUS

CN Acetic acid, [4-[[5,6-bis(4-methylphenyl)pyrazinyl](1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)




RN 475085-62-2 CAPLUS

CN Acetic acid, [4-[(3-chloro-5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)



RN 475085-93-9 CAPLUS


CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butyl]thio]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 475085-94-0 CAPLUS

CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 475085-95-1 CAPLUS

CN Acetic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-01-2 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 475086-02-3 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-03-4 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-05-6 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-07-8 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-10-3 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 475086-12-5 CAPLUS

CN Acetamide, N-[(4-chlorophenyl)sulfonyl]-2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)



RN 475086-14-7 CAPLUS


CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 475086-16-9 CAPLUS


CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-[(4-

fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 475086-18-1 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 475086-20-5 CAPLUS

CN Acetamide, N-(aminosulfonyl)-2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)




RN 475086-22-7 CAPLUS

CN Acetamide, N-[(dimethylamino)sulfonyl]-2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)




RN 475086-23-8 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 475086-24-9 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 475086-28-3 CAPLUS

CN Acetamide, 2-[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]- (9CI) (CA INDEX NAME)



RN 475086-29-4 CAPLUS


CN Sulfamic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 475086-31-8 CAPLUS

CN Sulfamic acid, [[4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]acetyl]-, monosodium salt (9CI) (CA INDEX NAME)





● Na


IT 475086-74-9P 475086-75-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of derivs. of heterocyclic compds. as antagonists of prostaglandin I2 receptor platelet aggregation inhibitor, or remedy for chronic artery obstruction, intermittent limping, or peripheral artery embolism)


RN 475086-74-9 CAPLUS

CN Pyrazinamine, N-(4-bromobutyl)-N-(1-methylethyl)-5,6-diphenyl- (9CI) (CA INDEX NAME)



RN 475086-75-0 CAPLUS

CN 1-Butanol, 4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AB Analogs of the light-producing substrate 2-methyl-6-(4-methoxyphenyl)imidazo[1,2- $\alpha$ ]pyrazin-3(7H)-one, with restrictions on the dihedral angles between the pyrazine and the 4-methoxyphenyl rings,

were synthesized. These compds. were used to investigate the effects of the conformation between the pyrazine and 4-methoxyphenyl rings on their chemiluminescence efficiencies in aq. solns. The effects of the conformation on the chemiluminescence efficiencies were clearly obsd.; the decrease of the dihedral angle caused a light-enhancing effect and, conversely, the increase of the angle dramatically decreased the chemiluminescence efficiency. These effects on the chemiluminescence efficiencies are attributed to the influence of the conformation on the fluorescence efficiency of the emitter.

ACCESSION NUMBER: 2002:50363 CAPLUS  
 DOCUMENT NUMBER: 136:294468  
 TITLE: Effect of conformation on the chemiluminescence efficiency of light-producing 2-methyl-6-(4-methoxyphenyl)imidazo[1,2- $\alpha$ ]pyrazin-2(7H)-ones  
 AUTHOR(S): Teranishi, Katsunori  
 CORPORATE SOURCE: Faculty of Bioresources, Mie University, Mie, 514-8507, Japan  
 SOURCE: Luminescence (2001), 16(6), 367-374  
 CODEN: LUMIFC; ISSN: 1522-7235  
 PUBLISHER: John Wiley & Sons Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 407605-10-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; effect of conformation on chemiluminescence efficiency of light-producing 2-methyl-6-(4-methoxyphenyl)imidazo[1,2- $\alpha$ ]pyrazin-2(7H)-ones)  
 RN 407605-10-1 CAPLUS  
 CN L-Alanine, N-[5-(4-methoxyphenyl)-6-methylpyrazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
 AB Antioxidants, 5 2-amino-(p-hydroxyphenyl)pyrazines and 3 (p-hydroxyphenyl)-3,7-dihydroimidazo[1,2-a]pyrazin-3-ones were prepd. and claimed useful in diagnostic procedures, as food additives, polymer additives and as UV screens in cosmetics. E.g., 2-amino-3,5-dibromopyrazine was treated with p-methoxyphenylboronic acid in the presence of bis(benzonitrile)palladium dichloride and 1,4-bis(diphenylphosphino)butane in a solvent mix of EtOH, aq. sodium carbonate and toluene to give 66% 2-amino-3,5-bis(p-methoxyphenyl)pyrazine, which was demethylated with EtSNa in DMF to give 88% 2-amino-3,5-bis(p-hydroxyphenyl)pyrazine (I). In tests on inhibition

of lipid peroxidn. 2-aminopyrazines possessing 2 aryl substituents, one of them being a p-hydroxyphenyl in o- or p- position with respect to the amino group, are endowed with antioxidative properties. However, the p-hydroxyphenyl conferred more activity when located at position 5 than at position 3. The presence of p-hydroxyphenyl groups at both positions 3 and 5 as in I produced a very active compd. Analogs lacking the free phenol groups showed reduced activities. Corresponding imidazolopyrazinones combined the properties of both the imidazolopyrazinones (delay of the onset of peroxidn.) and the aminopyrazines (lower rate of oxidn. after onset).

ACCESSION NUMBER: 2001:851130 CAPLUS  
 DOCUMENT NUMBER: 135:371764  
 TITLE: Prepn. of aminopyrazines and imidazolopyrazinones as antioxidants  
 INVENTOR(S): Marchand-Brynaert, Jacqueline; Cavalier, Jean-Francois; Rees, Jean-Francois; De Tollenaere, Catherine; Burton, Maggi  
 PATENT ASSIGNEE(S): Universite Catholique de Louvain, Belg.  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087853	A1	20011122	WO 2001-EP5588	20010516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1292580	A1	20030319	EP 2001-943383	20010516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: EP 2000-870107 A 20000517  
 EP 2000-870293 A 20001212  
 WO 2001-EP5588 W 20010516


OTHER SOURCE(S): CASREACT 135:371764; MARPAT 135:371764

IT 350230-61-4P 374588-74-6P

RL: FFD (Food or feed use); MOA (Modifier or additive use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aminopyrazines and imidazolopyrazinones as antioxidants)

RN 350230-61-4 CAPLUS

CN Alanine, N,N'-[3,5-bis(4-hydroxyphenyl)-2,6-pyrazinediyl]bis-, diethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 374588-74-6 CAPLUS


CN L-Alanine, N,N'-[3,5-bis(4-hydroxyphenyl)-2,6-pyrazinediyl]bis-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
GI



AB Arylpyrazine compds. I [Ar = substituted Ph, naphthyl, heterocyclyl; R1, R3 = H, halo, cyano, NO2, etc.; R2 = halo, amino, alkyl, etc.], including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors, were prepd. E.g., N-(1-ethylpropyl)-5-(2,4-dimethoxyphenyl)-3,6-dimethylpyrazine-2-amine was prepd. by reaction of 2-chloro-3,6-dimethylpyrazine with 1-ethylpropylamine, followed by bromination and reaction with 2,4-dimethoxybenzeneboronic acid.

ACCESSION NUMBER: 2001:617986 CAPLUS

DOCUMENT NUMBER: 135:180787

TITLE: Preparation of substituted arylpyrazines and their binding with CRF1 receptors

INVENTOR(S): Yoon, Taeyoung; Ge, Ping; Horvath, Raymond F.; De Lombaert, Stephane; Hodgetts, Kevin J.; Doller, Dario; Zhang, Cunyu

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001060806	A2	20010823	WO 2001-US5264	20010216
WO 2001060806	A3	20020207		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1255740	A2	20021113	EP 2001-910939	20010216
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003018035	A1	20030123	US 2001-788315	20010216
BG 106968	A	20030430	BG 2002-106968	20020731
NO 2002003869	A	20020911	NO 2002-3869	20020815
PRIORITY APPLN. INFO.:			US 2000-182934P	P 20000216
			US 2000-206455P	P 20000522
			WO 2001-US5264	W 20010216

OTHER SOURCE(S): MARPAT 135:180787


IT 355834-56-9P 355835-13-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of substituted arylpyrazines and their binding with CRF1 receptors)


RN 355834-56-9 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)



RN 355835-13-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



IT 355834-36-5P 355834-37-6P 355834-38-7P  
 355834-39-8P 355834-40-1P 355834-41-2P  
 355834-44-5P 355834-45-6P 355834-46-7P  
 355834-47-8P 355834-52-5P 355834-54-7P  
 355834-55-8P 355834-57-0P 355834-58-1P  
 355834-59-2P 355834-60-5P 355834-62-7P  
 355834-63-8P 355834-64-9P 355834-66-1P  
 355834-67-2P 355834-68-3P 355834-69-4P  
 355834-70-7P 355834-71-8P 355834-75-2P  
 355834-76-3P 355834-77-4P 355834-80-9P  
 355834-81-0P 355834-82-1P 355834-84-3P  
 355834-87-6P 355834-88-7P 355834-98-9P  
 355834-99-0P 355835-00-6P 355835-02-8P  
 355835-03-9P 355835-06-2P 355835-07-3P  
 355835-10-8P 355835-11-9P 355835-12-0P  
 355835-14-2P 355835-15-3P 355835-16-4P  
 355835-17-5P 355835-18-6P 355835-19-7P  
 355835-20-0P 355835-21-1P 355835-22-2P  
 355835-23-3P 355835-24-4P 355835-25-5P  
 355835-27-7P 355835-30-2P 355835-31-3P  
 355835-32-4P 355835-33-5P 355835-34-6P  
 355835-35-7P 355835-36-8P 355835-37-9P  
 355835-38-0P 355835-41-5P 355835-42-6P  
 355835-43-7P 355835-44-8P 355835-45-9P  
 355835-49-3P 355835-51-7P 355835-56-2P  
 355835-57-3P 355835-58-4P 355835-59-5P  
 355835-60-8P 355835-61-9P 355835-62-0P  
 355835-63-1P 355835-64-2P 355835-65-3P  
 355835-66-4P 355835-67-5P 355835-68-6P  
 355835-69-7P 355835-97-1P 355835-98-2P  
 355835-99-3P 355836-00-9P 355836-01-0P  
 355836-02-1P 355836-03-2P 355836-04-3P


355836-39-4P 355836-40-7P 355836-41-8P  
 355836-42-9P 355836-44-1P 355836-45-2P  
 355836-46-3P 355836-47-4P 355836-48-5P  
 355836-49-6P 355836-53-2P 355836-54-3P  
 355836-55-4P 355836-56-5P 355836-57-6P  
 355836-58-7P 355836-59-8P 355836-61-2P  
 355836-62-3P 355836-63-4P 355836-64-5P  
 355836-65-6P 355836-67-8P 355836-68-9P  
 355836-69-0P 355836-71-4P 355836-72-5P  
 355836-73-6P 355836-74-7P 355836-75-8P  
 355836-76-9P 355836-77-0P 355836-78-1P  
 355836-79-2P 355836-80-5P 355836-81-6P  
 355836-83-8P 355836-84-9P 355836-86-1P  
 355836-87-2P 355836-88-3P 355836-89-4P  
 355836-90-7P 355836-91-8P 355836-95-2P  
 355836-99-6P 355837-00-2P 355837-02-4P  
 355837-08-0P 355839-94-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted arylpyrazines and their binding with CRF1 receptors)


RN 355834-36-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-37-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-38-7 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-39-8 CAPLUS

CN Pyrazinamine, 5-(3-chlorophenyl)-N-(1-ethylpropyl)-3,6-dimethyl- (9CI)  
(CA INDEX NAME)




RN 355834-40-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-41-2 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-44-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1-propylbutyl)- (9CI)  
(CA INDEX NAME)







RN 355834-45-6 CAPLUS

CN Pyrazinamine, 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)-  
(9CI) (CA INDEX NAME)

RN 355834-46-7 CAPLUS


CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-dimethyl-N-(1-propylbutyl)-  
(9CI) (CA INDEX NAME)

RN 355834-47-8 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-dimethyl-N-(1-propylbutyl)-  
(9CI) (CA INDEX NAME)


RN 355834-52-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-dimethyl-N-(1-propylbutyl)-  
(9CI) (CA INDEX NAME)




RN 355834-54-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-N-(1-ethylpropyl)-3,6-dimethyl-  
(9CI) (CA INDEX NAME)




RN 355834-55-8 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-57-0 CAPLUS


CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methyl-5-(2,4,6-trimethylphenyl)-  
(9CI) (CA INDEX NAME)



RN 355834-58-1 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI)

(CA INDEX NAME)




RN 355834-59-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-60-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-62-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-63-8 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-64-9 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-66-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-67-2 CAPLUS


CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-68-3 CAPLUS


CN Pyrazinamine, 3,6-diethyl-5-(4-methoxy-2-methylphenyl)-N-(1-methylpropyl)-  
(9CI) (CA INDEX NAME)

RN 355834-69-4 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-propylbutyl)- (9CI)  
(CA INDEX NAME)

RN 355834-70-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-71-8 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-(1-methylpropyl)-  
(9CI) (CA INDEX NAME)


RN 355834-75-2 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-76-3 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-77-4 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-80-9 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-81-0 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355834-82-1 CAPLUS

CN Pyrazinamine, 5-[4-(dimethylamino)-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355834-84-3 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-(2-methoxy-4,6-dimethylphenyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355834-87-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355834-88-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)



RN 355834-98-9 CAPLUS


CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-(1-ethylpropyl)-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 355834-99-0 CAPLUS


CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-dimethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)






RN 355835-00-6 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-N-[1-(methoxymethyl)propyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-02-8 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-03-9 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 355835-06-2 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-07-3 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-[1-(methoxymethyl)propyl]- (9CI) (CA INDEX NAME)




RN 355835-10-8 CAPLUS

CN Pyrazinamine, 3-bromo-6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-11-9 CAPLUS

CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 355835-12-0 CAPLUS

CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-14-2 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-15-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-fluoro- (9CI) (CA INDEX NAME)




RN 355835-16-4 CAPLUS

CN Pyrazinamine, 3-chloro-5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-  
(9CI) (CA INDEX NAME)




RN 355835-17-5 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-iodo-  
(9CI) (CA INDEX NAME)




RN 355835-18-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy-  
(9CI) (CA INDEX NAME)




RN 355835-19-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methyl-  
(9CI) (CA INDEX NAME)




RN 355835-20-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-6-ethyl-N-(1-ethylpropyl)-3-methyl-  
(9CI) (CA INDEX NAME)




RN 355835-21-1 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-  
(9CI) (CA INDEX NAME)



RN 355835-22-2 CAPLUS


CN Pyrazinamine, 6-chloro-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-  
(9CI) (CA INDEX NAME)




RN 355835-23-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-


(9CI) (CA INDEX NAME)



RN 355835-24-4 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl-  
(9CI) (CA INDEX NAME)

RN 355835-25-5 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-(4-methoxy-2-methylphenyl)-6-  
methyl- (9CI) (CA INDEX NAME)


RN 355835-27-7 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-(methylthio)- (9CI) (CA INDEX NAME)




RN 355835-30-2 CAPLUS

CN 1-Butanol, 2-[[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 355835-31-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-32-4 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[4-methoxy-2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-33-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-34-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[4-methoxy-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-35-7 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-methoxy-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-36-8 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(trifluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)



RN 355835-37-9 CAPLUS


CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)






RN 355835-38-0 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)-(9CI) (CA INDEX NAME)




RN 355835-41-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-5-(2-methoxy-4,6-dimethylphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-(9CI) (CA INDEX NAME)




RN 355835-42-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]-(9CI) (CA INDEX NAME)




RN 355835-43-7 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]-(9CI) (CA INDEX NAME)




RN 355835-44-8 CAPLUS

CN Pyrazinamine, 5-[2,4-dimethyl-6-[2-(4-morpholinyl)ethoxy]phenyl]-3,6-diethyl-N-[2-methoxy-1-(methoxymethyl)ethyl]- (9CI) (CA INDEX NAME)




RN 355835-45-9 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 355835-49-3 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4,6-bis(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-51-7 CAPLUS

CN 1,2-Propanediamine, N2-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazinyl]-N1,N1-dimethyl- (9CI) (CA INDEX NAME)




RN 355835-56-2 CAPLUS

CN Pyrazinamine, 5-(2,4-diethoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI)  
(CA INDEX NAME)




RN 355835-57-3 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methoxy- (9CI)  
(CA INDEX NAME)




RN 355835-58-4 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-ethoxy- (9CI)  
(CA INDEX NAME)




RN 355835-59-5 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 355835-60-8 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-(difluoromethoxy)- (9CI) (CA INDEX NAME)




RN 355835-61-9 CAPLUS

CN Phenol, 4-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 355835-62-0 CAPLUS

CN Pyrazinamine, 5-(4-ethoxy-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-63-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355835-64-2 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(1-methylethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-65-3 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(difluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-66-4 CAPLUS

CN Phenol, 2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 355835-67-5 CAPLUS

CN Ethanol, 2-[2-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]-5-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 355835-68-6 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-[2-(2-methoxyethoxy)-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 355835-69-7 CAPLUS

CN Pyrazinamine, 5-[2-[2-(dimethylamino)ethoxy]-4-methylphenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-97-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethoxy-6-ethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355835-98-2 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-3,6-dimethoxy-(9CI) (CA INDEX NAME)




RN 355835-99-3 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy-(9CI) (CA INDEX NAME)




RN 355836-00-9 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy-(9CI) (CA INDEX NAME)




RN 355836-01-0 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[4-methoxy-2-(trifluoromethoxy)phenyl]-(9CI) (CA INDEX NAME)




RN 355836-02-1 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-03-2 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355836-04-3 CAPLUS


CN Pyrazinamine, N-(1-ethylpropyl)-3,6-dimethyl-5-(2,4,6-trichlorophenyl)- (9CI) (CA INDEX NAME)



RN 355836-39-4 CAPLUS


CN Pyrazinamine, 5-(2,4-dimethoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)






RN 355836-40-7 CAPLUS

CN Pyrazinamine, 5-[4-bromo-2-(trifluoromethoxy)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-41-8 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-42-9 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-44-1 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 355836-45-2 CAPLUS

CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-46-3 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methoxyphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-47-4 CAPLUS

CN Pyrazinamine, 5-(2,6-dichloro-4-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 355836-48-5 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(3-methyl[1,1'-biphenyl]-4-yl)-(9CI) (CA INDEX NAME)




RN 355836-49-6 CAPLUS

CN Pyrazinamine, 5-[2,4-bis(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy-(9CI) (CA INDEX NAME)




RN 355836-53-2 CAPLUS

CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl-(9CI) (CA INDEX NAME)




RN 355836-54-3 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl-(9CI) (CA INDEX NAME)




RN 355836-55-4 CAPLUS

CN Pyrazinamine, 5-[4-chloro-2-(trifluoromethyl)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-56-5 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-6-methoxy-5-[2-methyl-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-57-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-58-7 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-59-8 CAPLUS

CN Carbonodithioic acid, O-[3-chloro-4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-61-2 CAPLUS

CN Pyrazinamine, 3,6-diethyl-N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-(9CI) (CA INDEX NAME)




RN 355836-62-3 CAPLUS

CN Pyrazinamine, 5-(2-chloro-4-methylphenyl)-3,6-diethyl-N-(1-ethylpropyl)-(9CI) (CA INDEX NAME)




RN 355836-63-4 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-(1-ethylpropyl)-(9CI) (CA INDEX NAME)




RN 355836-64-5 CAPLUS

CN Carbonodithioic acid, O-[3-chloro-4-[3,6-diethyl-5-[(1-ethylpropyl)amino]pyrazinyl]phenyl] S-propyl ester (9CI) (CA INDEX NAME)




RN 355836-65-6 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2,6-dimethoxyphenyl)-3-ethoxy-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-67-8 CAPLUS

CN Pyrazinamine, 5-[4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-68-9 CAPLUS

CN Pyrazinamine, 5-(4-ethoxy-2,6-dimethoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-69-0 CAPLUS

CN Pyrazinamine, 5-(2,6-dimethoxy-4-methylphenyl)-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-71-4 CAPLUS

CN Benzenemethanol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3,5-dimethoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)




RN 355836-72-5 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-ethoxyphenyl)-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-73-6 CAPLUS

CN Pyrazinamine, 3-ethyl-5-(2-ethyl-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-74-7 CAPLUS

CN Pyrazinamine, 5-(4-chloro-2-methoxyphenyl)-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-75-8 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-methylethoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-76-9 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-6-ethyl-N-(1-ethylpropyl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-77-0 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)






RN 355836-78-1 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl-  
(9CI) (CA INDEX NAME)


RN 355836-79-2 CAPLUS

CN Pyrazinamine, 5-[2'-chloro-4',5-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]-N-(1-ethylpropyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-80-5 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methoxy-3-methyl- (9CI) (CA INDEX NAME)




RN 355836-81-6 CAPLUS

CN Pyrazinamine, 5-(2,4-dimethylphenyl)-N-(1-ethylpropyl)-6-methoxy-3-methyl-  
(9CI) (CA INDEX NAME)




RN 355836-83-8 CAPLUS

CN Pyrazinamine, 5-[4-ethoxy-2-(1-methylethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-84-9 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(1-ethylpropoxy)phenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-86-1 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-5-[4-(1-fluoroethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-87-2 CAPLUS

CN Pyrazinamine, 5-[2-chloro-4-(2-methoxyethoxy)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-88-3 CAPLUS

CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-89-4 CAPLUS

CN Pyrazinamine, 5-[4-[(dimethylamino)methyl]-2-methoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-90-7 CAPLUS

CN Benzenemethanol, 4-[5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 355836-91-8 CAPLUS

CN Pyrazinamine, 5-[4-(difluoromethoxy)-2-methoxyphenyl]-3-ethyl-N-(1-ethylpropyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 355836-95-2 CAPLUS

CN Pyrazinamine, N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-99-6 CAPLUS

CN Phenol, 4-[3-ethyl-5-[(1-ethylpropyl)amino]-6-methoxypyrazinyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 355837-00-2 CAPLUS


CN Pyrazinamine, 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355837-02-4 CAPLUS


CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[4-fluoro-2-

(trifluoromethyl)phenyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 355837-08-0 CAPLUS

CN Pyrazinamine, N-(1-ethylbutyl)-6-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 355839-94-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



IT 355836-19-0P 355836-20-3P 355836-27-0P


355836-28-1P 355836-29-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of substituted arylpyrazines and their binding with CRF1 receptors)

RN 355836-19-0 CAPLUS

CN Pyrazinamine, 5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 355836-20-3 CAPLUS

CN Pyrazinamine, 3-bromo-5-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-6-methyl-  
(9CI) (CA INDEX NAME)


RN 355836-27-0 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 355836-28-1 CAPLUS

CN Pyrazinamine, 3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-, 4-oxide (9CI) (CA INDEX NAME)



RN 355836-29-2 CAPLUS

CN Pyrazinamine, 6-chloro-3-ethyl-N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AB The coupling of arylboronic acids with 2,6-diamino-3,5-dibromopyrazine gave 2,6-diamino-3,5-diaryl-1,4-pyrazines. The reaction of the latter with Me glyoxal in aq. EtOH-HCl gave N,N'-disubstituted products, instead of the expected bicyclic imidazolopyrazinones. These 2,6-bis[1-(ethoxycarbonyl)ethylamino]-3,5-diaryl-1,4-pyrazines are powerful inhibitors of the AAPH-induced linoleate peroxidn.

ACCESSION NUMBER: 2001:321697 CAPLUS

DOCUMENT NUMBER: 135:107305

TITLE: 2,6-diamino-3,5-diaryl-1,4-pyrazine derivatives as novel antioxidants

AUTHOR(S): Cavalier, Jean-Francois; Burton, Maggi; De Tollenaere, Catherine; Dussart, Frederique; Marchand, Cecile; Rees, Jean-Francois; Marchand-Brynaert, Jacqueline

CORPORATE SOURCE: Unite de Chimie Organique et Medicinale, Universite Catholique de Louvain, Louvain-la-Neuve, 1348, Belg.

SOURCE: Synthesis (2001), (5), 768-772

CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:107305


IT 350230-60-3P 350230-61-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and antioxidant activity of diphenylpyrazinediamine and (hydroxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one derivs.)

RN 350230-60-3 CAPLUS


CN Alanine, N,N'-(3,5-diphenyl-2,6-pyrazinediyl)bis-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 350230-61-4 CAPLUS

CN Alanine, N,N'-[3,5-bis(4-hydroxyphenyl)-2,6-pyrazinediyl]bis-, diethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
 AB Improved chemiluminescent probes for superoxide ion are described. Eleven novel coelenterazine analogs, having the common structure of 3,7-dihydroimidazo-[1,2-a]pyrazin-3-one ring system (I), were synthesized. The properties of superoxide ion-triggered chemiluminescence of these compds., coelenterazine and 3 known coelenterazine analogs in the hypoxanthine-xanthine oxidase (hypoxanthine-XO) system were investigated, clarifying that alkyl substitution at the C-5 position of I, except for cyclization between the C-5 position and the Ph group at the C-6 position, drastically reduces the intensity of superoxide ion-dependent chemiluminescence. The luminescent intensity of the bridged analog was 33-fold stronger than that of 2-methyl-6-(4-methoxyphenyl)-3,7-dihydroimidazo-[1,2-a]pyrazin-3-one (MCLA), which is the best of the Cypridina luciferin analogs used as chemiluminescent probe, at the most optimal concn. of luminescent substrates in the simple hypoxanthine-XO system. Cyclodextrin-bound coelenterazine analogs showed desirable properties; soly. in water was suitable and the superoxide-dependent chemiluminescent intensity was stronger than that of MCLA and was not influenced by bovine serum albumin.

ACCESSION NUMBER: 1998:522957 CAPLUS  
 DOCUMENT NUMBER: 129:287445  
 TITLE: Oversea research scholar report in marine biological laboratory from february 1st to may 31st, 1996: 3, 7-Dihydroimidazo-[1, 2-a]pyrazin-3-ones as chemiluminescent probe with improved sensitivity to superoxide ion  
 AUTHOR(S): Teranishi, Katsunori  
 CORPORATE SOURCE: Faculty of Bioresources, Mie University, Mie, 514-8507, Japan  
 SOURCE: Bulletin of the Faculty of Bioresources, Mie University (1997), 19, 29-43  
 CODEN: BFBUEF; ISSN: 0915-0471  
 PUBLISHER: Mie Daigaku Seibutsu Shigengakubu  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 204770-58-1P 204770-62-7P




RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of dihydroimidazopyrazinones as chemiluminescent probes with improved sensitivity to superoxide ion)


RN 204770-58-1 CAPLUS

CN Glutamic acid, N-[5-(4-methoxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI)  
(CA INDEX NAME)



RN 204770-62-7 CAPLUS

CN Glutamic acid, N-[5-(4-methoxyphenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN


AB In order to provide chemiluminescent substrates that have high light-emitting efficiency in aq. soln., the structural design on 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one compds. was studied in the covalent attachment of a light-producing chromophore to a cyclomaltooligosaccharide (cyclodextrin). The synthesis of cyclodextrin-bound 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one compds. was achieved by the formation of an amido bond between a 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one and a mono-6-amino-6-deoxycyclodextrin. The properties of oxygen-induced chemiluminescence of the synthesized cyclodextrin-bound light-emitting chromophores were investigated. The light-emitting efficiency in pH 8.3 phosphate buffer was remarkably dependent on the kind of bound cyclodextrin and the binding site between the chromophore and cyclodextrin. The light-emitting efficiency of a cyclodextrin-bound compd. in which cyclomaltoheptaose (.beta.-cyclodextrin) had been covalently attached to the 2-position of the imidazo[1,2-a]pyrazin-3(7H)-one ring system showed an up to 11-fold enhancement over that of a non-cyclodextrin chromophore, whereas attachment to cyclomaltohexaose (.alpha.-cyclodextrin) resulted in no enhancement. Moreover, this study indicated that the strategy that involves covalently attaching a light-producing chromophore onto a cyclodextrin for the enhancement of chemiluminescence is more efficient than the use of an aq. soln. contg. very large amts. of cyclodextrin.

ACCESSION NUMBER: 1998:454164 CAPLUS

DOCUMENT NUMBER: 129:203163

TITLE: Synthesis and enhanced chemiluminescence of new cyclomaltooligosaccharide (cyclodextrin) -bound

AUTHOR(S): 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one  
Teranishi, Katsunori; Komoda, Atsuko; Hisamatsu,  
Makoto; Yamada, Tetsuya  
CORPORATE SOURCE: Faculty of Bioresources, Mie University, Mie, 514,  
Japan  
SOURCE: Carbohydrate Research (1998), 306(1-2), 177-187  
CODEN: CRBRAT; ISSN: 0008-6215  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 204770-62-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and enhanced chemiluminescence of cyclomaltooligosaccharide  
cyclodextrin bound 6-phenylimidazo[1,2-a]pyrazin-3-one)  
RN 204770-62-7 CAPLUS  
CN Glutamic acid, N-[5-(4-methoxyphenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB Fluorescent cyclodextrins I, II [R1 = H, C1-6 alkyl, C1-6 alkoxy; R2 = H, C1-6 (un)substituted alkyl; R3 = Q; m = 0-5; n = 6-8], and their salts, useful for optical devices and sensors (no data), are prep'd. by condensation of imidazopyrazines I, II (R1, R2, m = same as above; R3 = OH), or their salts with 6-monodeoxyaminocyclodextrin. I.HCl (R1 = MeO, R2 = CH2Ph, R3 = OH) was treated with mono-6-deoxy-6-amino-.alpha.-cyclodextrin and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl salt at 0.degree. for 14 h in pyridine to give 26% I (R1 = MeO, R2 = CH2Ph, R3 = Q, n = 6).

ACCESSION NUMBER: 1998:184331 CAPLUS  
DOCUMENT NUMBER: 128:244282  
TITLE: Preparation of fluorescent cyclodextrins and  
imidazopyrazines as their intermediates  
INVENTOR(S): Teranishi, Katsumichi; Komoda, Junko; Hisamatsu,  
Makoto; Yamada, Tetsuya  
PATENT ASSIGNEE(S): Japan Maize Products Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1


## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10077286	A2	19980324	JP 1996-235584	19960905


PRIORITY APPLN. INFO.: JP 1996-235584 19960905  
 OTHER SOURCE(S): MARPAT 128:244282  
 IT 204770-58-1P 204770-62-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of fluorescent cyclodextrins and imidazopyrazines as their intermediates for optical devices and sensors)  
 RN 204770-58-1 CAPLUS  
 CN Glutamic acid, N-[5-(4-methoxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI)  
 (CA INDEX NAME)



RN 204770-62-7 CAPLUS  
 CN Glutamic acid, N-[5-(4-methoxyphenyl)pyrazinyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN  
 GI




I


AB Effects of conformation rigidity and H-bonding with the emitter coelenteramide, on the chemiluminescence efficiency of coelenterazine (I) were examd. with several coelenterazine analogs. Conformational rigidity has a light-enhancing effect, whereas decreasing light yield was obsd. by

H-bond formation with the emitter.


ACCESSION NUMBER: 1991:101506 CAPLUS  
 DOCUMENT NUMBER: 114:101506  
 TITLE: Synthesis and chemiluminescence of coelenterazine  
 (Oplophorus luciferin) analogs  
 AUTHOR(S): Teranishi, Katsunori; Goto, Toshio  
 CORPORATE SOURCE: Fac. Agric., Nagoya Univ., Nagoya, 464, Japan  
 SOURCE: Bulletin of the Chemical Society of Japan (1990),  
 63(11), 3132-40  
 CODEN: BCSJA8; ISSN: 0009-2673  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 114:101506  
 IT 132063-77-5P 132063-80-0P 132063-82-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and intramol. cyclocondensation of, imidazopyrazine from)  
 RN 132063-77-5 CAPLUS  
 CN Tyrosine, N-[5-(4-hydroxyphenyl)-6-methyl-3-(phenylmethyl)pyrazinyl]-  
 (9CI) (CA INDEX NAME)



RN 132063-80-0 CAPLUS  
 CN Tyrosine, N-[6-(2-hydroxyethyl)-5-(4-hydroxyphenyl)-3-(phenylmethyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 132063-82-2 CAPLUS  
 CN Tyrosine, N-[5-[4-(dimethylamino)phenyl]-3-(phenylmethyl)pyrazinyl]- (9CI)  
 (CA INDEX NAME)



IT 132063-87-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 132063-87-7 CAPLUS

CN Tyrosine, N-[5-(4-hydroxyphenyl)-6-methyl-3-(phenylmethyl)pyrazinyl]-,  
methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

GI For diagram(s), see printed CA Issue.

AB For the purpose of clarifying the chemiluminescence mechanism of Cypridina luciferin (I), 3,7-dihydroimidazo[1,2-a]pyrazin-3-one (IIa) as the simplest, but rather unstable analog of I and its 2-Me (IIb), 2-Ph (IIc), and 6-Ph (IId) derivs. were synthesized. 2-Aminopyrazines or 2-chloropyrazines were converted into pyrazylglycine and its .alpha.-substituted derivs. (III), their amides (IV), or their esters (V), either of which could be cyclized to the corresponding imidazopyrazinones (II). Cyclization of esters by means of Na alkoxide was preferable to the acidic condition (by HCl) reported by McCapra (1967).

ACCESSION NUMBER: 1970:445459 CAPLUS

DOCUMENT NUMBER: 73:45459

TITLE: Synthesis of Cypridina luciferin and related  
compounds. 4. Synthesis of 3,7-dihydroimidazo[1,2-  
.alpha.]pyrazin-3-ones

AUTHOR(S): Sugiura, Sumi; Inoue, Shoji; Goto, Toshio

CORPORATE SOURCE: Fac. Pharm., Meijo Univ., Nagoya, Japan

SOURCE: Yakugaku Zasshi (1970), 90(4), 423-30

CODEN: YKKZAJ; ISSN: 0031-6903

DOCUMENT TYPE: Journal

LANGUAGE: Japanese


IT 28111-46-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 28111-46-8 CAPLUS

CN Alanine, N-(5-phenylpyrazinyl)-, ethyl ester, L- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 14:09:20 ON 19 SEP 2003)

FILE 'REGISTRY' ENTERED AT 14:09:28 ON 19 SEP 2003

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 STRUCTURE UPLOADED

L4 10 S L3

L5 198 S L3 FUL

FILE 'CAPLUS' ENTERED AT 14:11:26 ON 19 SEP 2003

L6 10 S L5